QIAGEN officially confirmed a global cooperation agreement with Sysmex Corporation for the development and commercialization of cancer companion diagnostics, leveraging both QIAGEN’s expertise in this field and Sysmex’s Plasma-Safe-SeqS platform for next-generation sequencing (NGS).
Advancing the use of NGS technologies in clinical decision-making
Tumor genetic analysis identifies the genes responsible for tumor growth and spread, allowing treatment to be targeted accordingly. Traditional solid tumor analysis, on the other hand, is limited by heterogeneity — for example, variable concentrations of cancer cells – and by sample availability. Liquid biopsy overcomes these obstacles and, when combined with sensitive NGS, allows patients to be assessed at various stages of their cancer therapy. It enables clinicians to detect new abnormalities, fine-tune treatments to improve precision and develop novel targeted therapies.
Alliance boosts QIAGEN’s co-development of companion diagnostics with drug makers
Jean-Pascal Viola, Senior Vice President, Head of the Molecular Diagnostics Business Area and Corporate Business Development at QIAGEN said:
“Combining QIAGEN’s global reach with Sysmex’s NGS capabilities is an important milestone in advancing the use of NGS technologies in clinical decision-making and is a testament to our shared vision of using this powerful technology to improve outcomes for patients worldwide. This alliance will add strong NGS capabilities to our regulatory and clinical expertise and commercialization, and help our partners in the pharmaceuticals industry by expanding our strong position and product offering in companion diagnostics. We look forward to this alliance creating significant benefits for our pharma partners – and ultimately for treating patients.”
Hiroshi Kanda, Member of the Managing Board and Senior Executive Officer, Head of Corporate Business Development at Sysmex commented:
“The alliance with QIAGEN promises Sysmex a great application for Sysmex’s Plasma-Safe-SeqS technology, which can detect gene mutations of cancer in blood with ultra-high sensitivity. We believe that QIAGEN is the best for Sysmex to expand this globally.”
Precision medicine was pioneered by QIAGEN, a German provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research, which is consolidated under the Dutch holding QIAGEN N.V.
QIAGEN is a world leader in partnering with pharmaceutical and biotechnology companies to co-develop companion diagnostics that identify genetic abnormalities and help clinicians make better decisions. The organisation offers an advanced range of technologies for companion diagnostics development, ranging from next-generation sequencing (NGS) to polymerase chain reaction (PCR). The FDA has authorized 10 PCR-based companion diagnostics products in QIAGEN’s portfolio, including therascreen EGFR for non-small cell lung cancer, therascreen KRAS for colorectal cancer and NSCL (including the G12C mutation), therascreen FGFR for urothelial cancer, therascreen PIK3CA for breast cancer based on tissue or plasma samples, and therascreen BRAF kit for colorectal cancer.
More than 25 businesses have signed strategic partnership agreements with QIAGEN to develop and market companion diagnostics for medicines in development, resulting in a pipeline of prospective products to advance precision medicine and benefit patients. QIAGEN has collaborated with Illumina to expand the use of companion and other in-vitro diagnostics (IVD) kits based on next-generation sequencing (NGS) in patient management.
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. QIAGEN’s sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of March 31, 2021, QIAGEN employed approximately 5,700 people in over 35 locations worldwide.
Further information can be found at http://www.qiagen.com.
Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed on the first section of the Tokyo Stock Exchange.
For more information about Sysmex Corporation and its affiliate companies, please visit http://www.sysmex.co.jp/en/.